Pharmaceutical companies have taken the initiative to withdraw the network, and another 52 drugs will be suspended nationwide

"Pharmaceutical Network Industry Dynamics" Recently, the Inner Mongolia Pharmaceutical Mining Center issued "on the cancellation of Heilongjiang Province Jiren Pharmaceutical Co., Ltd. and other enterprises produced part of the drug registration network qualification notice."
the notice, 24 pharmaceutical companies applied to disqualify the drug network, and submitted a unified national commitment not to supply, involving a total of 52 drugs.
25 of them are Chinese medicine, 27 are chemicals, most of them are low-cost drugs, cheap drugs.
from the contents of the notice, the 52 drugs applied for a nationwide suspension of supply, including production line rectification and upgrading, production stoppage and so on.
In fact, we are no strangers to drug companies taking the initiative to disqualify themselves from the Internet, or even promising a unified national non-supply initiative, which has become a common occurrence in drug recruitment in recent years.
September 14, the Guizhou Provincial Public Resources Trading Center announced that it would cancel the 22 drugs winning the bid (hanging net) of the notice.
According to the document, some enterprises due to production line transformation, production stoppage and other reasons, drugs have been unable to guarantee supply, submitted an application to cancel their products in Guizhou Province drug centralized procurement of the winning bid (hanging net) qualification, and promised that from the date of cancellation, the enterprise with the same product regulations products for two years may not participate in the centralized procurement activities of drugs in Guizhou Province.
May 21, Shanxi Province, the centralized bidding procurement network issued two consecutive notices, Chenxin Pharmaceutical Co., Ltd., Chengdu Teo Pharmaceutical Group Co., Ltd. and other 25 pharmaceutical production enterprises 66 product regulations, apply to revoke the direct hanging network product platform registration qualification.
according to the "Notice" shows that the relevant pharmaceutical companies also provide a unified national commitment not to supply, related products will gradually withdraw from the national pharmaceutical market.
January 8, Hainan Province Pharmaceutical Centralized Purchasing Center issued the "Notice on the publicity of part of the drug withdrawal network (2020.01.08)," 250 drug applications to cancel the network.
Of these, 171 drugs were discontinued due to rising production costs, inability to supply normally, line modifications, production line stops, etc., 28 drugs were discontinued due to price increases or shortages of API, and 15 drugs were discontinued due to the upside-down price and cost of the winning bid.
from the announcement issued in various places can be seen that pharmaceutical companies choose the national unified non-supply of the main reason is to stop production, and stop production generally involves raw material prices, production line transformation, environmental pollution and other reasons.
analysts pointed out that in recent years, under the reform of the drug review and approval system to encourage drug innovation, with volume procurement squeeze the middle link moisture, cut off the gold sales chain, consistent evaluation to promote generic drugs clinical replacement of high-priced original research drugs, as well as focus on monitoring and strengthening clinical rational drug use and other policies, China's pharmaceutical market pattern is changing dramatically.
the sale price of some drug markets has been unable to support high production costs, production enterprises to give up some of the less profitable product market has been an inevitable choice.
generally believe that a series of medical reforms will bring great pressure to domestic production enterprises, but also to China's pharmaceutical industry to go to the pain of production capacity.
past, products through marketing, price war, can be based in the market "boom", no longer exists.
, through the promotion of national medical reform, enterprise response, drug market concentration will gradually strengthen, the head effect will be more obvious, and the price of drugs will be more and more reasonable.